Enosi Founder Feldmann Advocates Anti-TNF Research for COVID

экрана 2020 07 18 в 09.15.49
Trials of Anti-TNF Therapy for COVID-19 are Urgently Needed

Following extremely promising, early data results, Enosi Life Sciences Co-Founder and Chairman Professor Sir Marc Feldmann is leading a team of global researchers in advocating for current, approved, TNF Blockers to be used to treat #COVID-19 patients in severe respiratory distress – helping them to avoid dependence on mechanical respirators. This article appeared in The Lancet, “Doctopic: Analysis & Interpretation”. Enosi’s next generation TNFR1 blocker is more specific and will enhance the body’s own anti-inflammatory response.

Dr. Shepard Accepts Lasker-DeBakey Medical Research Award

Upon receiving the 2019 Lasker-DeBakey Clinical Medical Research Award – among biosciences’ most prestigious honors worldwide – Dr. H. Michael Shepard shared both his experiences as a scientist inventing “Herceptin”; as well as his views regarding how the scientific community may best foster the next generation of scientific breakthroughs.

NIH Interviews Sir Marc Feldmann Regarding Anti-TNF Research

Lasker Award Winner and University of Oxford Professor Sir Marc Feldmann was interviewed by the National Institutes of Health Dr. William Paul regarding Sir Marc’s research identifying TNF’s role in autoimmune diseases – and the resulting, Anti-TNF therapeutics developed to block inflammation and chronic pain.

2019 Lasker Award Describes Invention of Herceptin

The 2019 Lasker~DeBakey Clinical Medical Research Award honors Michael Shepard, Dennis Slamon, and Axel Ullrich for the invention of Herceptin, the first monoclonal antibody that blocks a cancer-causing protein, and for its development as a life-saving therapy for women with breast cancer.

Sir Marc Feldmann Interview "Giants of Medicine"

Sir Marc Feldmann is interviewed by the Journal of Clinical Investigation regarding his research understanding autoimmune disease-specifically the treatment of rheumatoid arthritis (RA) – and the role of TNF and subsequent TNF Blockers.

Articles

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.